Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Regeneron’s George Yancopoulos Becomes Pharma’s First Billionaire R&D Chief

Twenty-seven years ago George Yancopoulos was a scientific superstar, a professor of biology at Columbia at age 28. But his father, a first-generation Greek immigrant, kept complaining about how little academia paid. So Yancopoulos, now 55, signed on with a nascent Tarrytown, N.Y.-based biotech firm called Regeneron–and has since led the invention of four approved […]

Read More »

Pfizer’s revenue, profit beat as vaccine sales rise

Pfizer Inc on Tuesday reported better-than-expected second-quarter profit and revenue, helped by strong demand for its pneumonia vaccine and new breast cancer drug, sending its shares up 1 percent. The largest U.S. drugmaker, which raised its full-year earnings forecast, said revenue from its global vaccines unit rose 44 percent to $1.58 billion. The unit, which […]

Read More »

Merck raises forecast on strong sales of diabetes, cancer drugs

Merck & Co Inc (MRK.N) reported a better-than-expected quarterly profit and boosted its full-year earnings forecast as demand for its diabetes and cancer drugs increased. The company also said it expects to reap benefits from its $8.4 billion purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin. Cubicin sales for the second quarter were […]

Read More »

Some serious drug side effects not told to FDA within 15 days

Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds. Drug manufacturers are also less likely to disclose serious adverse events within this window when patient deaths are […]

Read More »

Horizon Pharma Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE (interferon gamma-1b) in Combination With PD-1/PD-L1 Inhibitors in Various Forms of Cancer

DUBLIN, IRELAND–(Marketwired – Jul 27, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms […]

Read More »

New heart drugs come in more expensive than expected

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too much. Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk […]

Read More »

The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease – and […]

Read More »

Regeneron and Sanofi Announce FDA Approval of Praluent (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. Praluent is indicated as an adjunct to […]

Read More »

AbbVie, Bristol-Myers get FDA nod for hep C treatments

The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections. The regulator cleared AbbVie Inc’s Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co’s Daklinza, used to treat HCV genotype 3 infections. About 2.7 million Americans are infected with HCV, of which […]

Read More »

Enanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE (ombitasvir, paritaprevir and ritonavir) tablets

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration (FDA) approved AbbVie’s TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets in combination with ribavirin (RBV) for the treatment of non-cirrhotic adults with genotype […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom